Developing the Future of Medicine
At JFK Medical Center, the following clinical trials have IRB approval for enrollment. JFK Medical Center is an Affiliate of the Rutgers Cancer Institute of New Jersey. As an Affiliate, access to other clinical trials is available.
JFK Medical Center Trials
Diffusion 100-206 – Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
STELLAR Study – A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. Orbus Therapeutics.
This study is for patients with first recurrence anaplastic astrocytoma aged > 18. Patients will be randomized to receive Lomustine or Eflornithine with Lomustine. Eflornithine (the study drug) is an irreversible inhibitor of ornithine decarboxylase. Ornithine decarboxylation reaction catalyzed by ornithine decarboxylase is the first and committed step in the synthesis of polyamines. Polyamines are important for stabilizing DNA structure, the DNA double strand-break repair pathway and as antioxidants. Therefore, ornithine decarboxylase is an essential enzyme for cell growth. Inhibition of this enzyme should slow tumor growth/progression.
Tg 511-15-01 – A Phase 2/3 Randomized Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard 511-15-01 of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Vigilant – Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
ZioPharma Study – A Study of Ad-RTS-hIL-12 With Veledimex in Subjects with Glioblastoma or Malignant Glioma
DLBCL: InCB 50465-202 – A phase 2 multicenter international open label safety and efficacy study of INCB 050465 in subjects with relapsed or refractory diffused large B cell lymphoma
Follicular/Marginal Zone/or Mantle Cell Lymphoma:
- Celgene CC-5013-NHL-008 – Magnify – A phase 3 B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide single agent maintenance vs rituxamab maintenance in subjects with relapsed/refractory follicular, marginal zone or mangle cell lymphoma
- INCB 50465-203 – A phase 2 multicenter open label study of INCB050465, a P13K inhibitor in relapsed or refractory follicular lymphoma
- INCB 50465-204 – Phase 2 open label 2 cohort study of INCB 050465 a P13K inhibitor in subjects with relapsed or refractory marginal zone lymphoma with or without prior exposure to a BTK inhibitor
- INCB 50465-205 – A phase 2 open label 2 cohort multicenter study of INCB 50465 a P14k inhibitor in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor
- Acerta ACE-LY-003 – Phase 1b/2 open label study of alcalabrutinib alone or in combination with rituxan in subjects with indolent b-cell NHL
Metastatic Disease: Horizon BCBS – Observational GPS study for patient with patients who have Horizon BCBS insurance and metastatic disease
Multiple Myeloma: Millenium C16021 – A phase 3 randomized, placebo-controlled double blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant
Ovarian Cancer: Astrazenca light D018161003 – Non randomized open label phase 2 study to access oliparib tablets as a treatment for subjects with different HRD tumor status and with platinum sensitive, relapsed, high grade or high grade endometriod ovarian, fallopian tube of primary periotoneal cancer that have received at least 1 prior line of chemo
Pancreatic: CanStem111P – Phase 3 open label randomized, study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemzar (arm 1) vs nab-paclitaxel with gemzar (arm 2) in metastatic disease